



excelra

GOBIOM Use Case 3



Identification of safety biomarkers evaluated against AMPK inhibitors



- ✓ A drug metabolism and pharmacokinetic group in a clinical research institute are working on safety and toxicity biomarkers against AMPK inhibitors
- ✓ Once the biomarkers have been identified, they intend to filter out best biomarkers to be included in their interventional clinical trial of new AMPK inhibitor
- ✓ The shortlisted safety biomarkers are expected to be measured in the clinical trial to determine dose-concentration-effect relationship

A search in GOBIOM database by keyword 'AMPK' in 'Target Name', keyword "Safety" in 'Application' retrieves all the safety biomarkers reported against AMPK inhibitors

Home / Search / Advanced Search

Selected Fields
 Safety ✕ AMP activated protein kinase ✕

Search Type
 Contains Starts With

Biomarker Clinical Status
 Clinical Exploratory Clinical Pre-Clinical Safety / Toxicity

Biomarker

Biomarker Name:

Biomarker Nature:

Biomarker Type:

Application:

Biomarker Qualification:

Biomarker Pathways:

Disease

Therapeutic Area:

Disease Name:

Disease Sub-type:

Disease Stage:

Disease Grade:

Clinical

Clinical Trial ID:

Sponsor / Collaborator:

Phase:

Completion Status:

Ethnicity:

Drug


Drug Name:

Drug Target:

Adverse Event:

Organ Disorder:

Organ Disorder Sub-type:



Results aid in identification of relevant safety biomarkers to

- ✓ Better understand early toxicity in animal studies
- ✓ Aid in initial dose selection in clinical studies
- ✓ Improve safety monitoring in phase 1 and 2 clinical trials

A search in GOBIOM database by keyword 'AMPK' in 'Target Name' and keyword "Pharmacokinetic" in 'Application' retrieves all the pharmacokinetic biomarkers reported against AMPK inhibitors

Home / Search / Advanced Search

Selected Fields
 Pharmacokinetic ✕ 5"-AMP-activated protein kinase subunit beta-1 ✕

Search Type
 Contains Starts With

Biomarker Clinical Status
 Clinical Exploratory Clinical Pre-Clinical Safety / Toxicity

Biomarker

Biomarker Name:

Biomarker Nature:

Biomarker Type:

Application:

Biomarker Qualification:

Biomarker Pathways:

Disease

Therapeutic Area:

Disease Name:

Disease Sub-type:

Disease Stage:

Disease Grade:

Clinical

Clinical Trial ID:

Sponsor / Collaborator:

Phase:

Completion Status:

Ethnicity:

Drug


Drug Name:

Drug Target:

Adverse Event:

Organ Disorder:

Organ Disorder Sub-type:



Number of Records : 2


10 Show entries Search:

Previous **1** Next

Watch	Visualization	EBMID	Biomarker Name	Disease Name	Biomarker Type	Biomarker Class	Biomarker Status	Approval Status	No of Applications	No of Drugs	No of Clinical Trials	No of References
<input type="checkbox"/>			MED-3631	GLUCAGON-LIKE PEPTIDE 1	Diabetes Mellitus, Type 2	Proteomic	Disease	Clinical	5	67	154	199
<input type="checkbox"/>			MED-6897	PEPTIDE YY	Diabetes Mellitus, Type 2	Proteomic	Disease	Clinical	4	15	21	30

Results aid in identification of relevant pharmacokinetic biomarkers to

- ✓ Effectively design interventional clinical trial with optimal drug dose and schedule
- ✓ Identify compounds that are likely to fail at later stages of development
- ✓ Select lead drug candidates in discovery



www.excelra.com

THANK YOU



Disclaimer: This communication is for the intended recipient. The whole or part of this communication should not be transmitted to any external entity or enterprise without the consent of Excelra Knowledge Solutions. If you have received this by mistake or you are not the intended recipient, kindly delete it and immediately inform us.

